Uncured articles with improved shelf-life

Information

  • Patent Grant
  • 11401204
  • Patent Number
    11,401,204
  • Date Filed
    Friday, February 6, 2015
    9 years ago
  • Date Issued
    Tuesday, August 2, 2022
    a year ago
Abstract
Disclosed are formaldehyde-free, thermally-curable, alkaline, aqueous binder compositions. Also disclosed are compositions comprising formaldehyde-free, thermally-curable binder compositions, as described herein, applied to non-woven fibers. Uses of the disclosed binder compositions as binders for non-woven fibers are also disclosed.
Description
TECHNICAL FIELD

This invention relates to binders and binder technology applicable in the preparation of compositions that include non-woven fibers. More particularly, the present invention relates to uncured mineral wool, i.e., uncured glass wool (fiberglass) and/or uncured stone wool, products (articles) prepared with formaldehyde-free binders that are cured (e.g., by molding) in a secondary step after the corresponding uncured products are collected.


BACKGROUND

So called “shipout uncured” and “plant uncured” fiberglass insulation is manufactured with an uncured, thermosetting binder. The resulting uncured insulation products are collected, packaged into rolls, bagged, and sealed in plastic bags. At various times thereafter, the bagged insulation material is i) transported to, ii) stored at, and iii) ultimately processed via a distinct separate manufacturing sequence by, a customer to yield a finished part. This manufacturing sequence includes heat curing of the binder. The time between collection of the uncured product and curing the binder can span several days to several weeks. In the case of “shipout uncured” fiberglass insulation, the uncured product is transported to customers that require the product to have a long shelf-life during ambient storage and transportation conditions. Ideally, “shipout uncured” fiberglass insulation has a minimum shelf-life of 2 to 4 weeks.


Standard binder for “shipout uncured” and “plant uncured” fiberglass insulation has historically been based on phenol-formaldehyde (PF) binder chemistry. PF binders exhibit the disadvantage of formaldehyde emissions. Binders based on reducing sugar carbohydrates for cured product lines are known in the art. Due to an increasingly uncertain regulatory situation as it pertains to the use of formaldehyde-containing binders and/or formaldehyde-liberating products, there has been steadily increasing interest in, if not demand for, a sustainable, formaldehyde-free binder based on carbohydrates for “shipout uncured” and “plant uncured” fiberglass insulation. Heretofore, the prior art has not described such a binder, or an equivalent binder composition, for such uncured fiberglass insulation products.


Initial trials aimed at discovering a carbohydrate-based binder for uncured fiberglass insulation product lines involved dextrose as the carbohydrate source. The resulting uncured product rolls displayed major disadvantages, which included the fact that: a) the dextrose-based binder crystallized out and caused poor loft and poor recovery when unrolling the fiberglass rolls, b) the dextrose-based binder migrated to the glass surface and segregated out into binder “islands,” which islands were noticeable after curing/molding as a darkly-colored dotted pattern, c) due to binder migration, the inner part of the fiberglass layer was depleted of binder whereas the outer pelt surface was binder rich, which depletion caused weakened integrity of the cured/molded product whereas binder enrichment and crystallization on the pelt surface resulted in poor handling characteristics when molding (i.e., binder rich areas tended to stick to the mold platens, which often resulted in the destruction of the molded part when removing it from the platen), and d) when a permeable membrane (e.g., non-woven glass veil) was used, binder rich spots often bled through the veil upon molding.


OBJECTS OF THE INVENTION

One object of the present invention is to provide a carbohydrate-based binder that enables the manufacture of uncured fiberglass insulation products with good shelf-life during ambient transportation and storage conditions (e.g., in winter and summer; in northern and southern climate).


Another object of the present invention is to provide a carbohydrate-based binder that does not significantly and/or noticeably migrate within finished uncured fiberglass insulation products with concomitant localized depletion of binder.


Another object of the present invention is to provide a carbohydrate-based binder that does not crystallize out in finished uncured fiberglass insulation products and thereby form dotted patterns therein after cure.


Yet another object of the present invention is to provide a carbohydrate-based binder that does not significantly and/or noticeably migrate within finished uncured fiberglass insulation products with concomitant localized enrichment of binder.


SUMMARY

One aspect of the present invention provides a carbohydrate-based binder in accordance with claim 1; the dependent claims define alternative and/or preferred embodiments.


In another illustrative aspect, the present invention provides a carbohydrate-based binder solution comprising a mixture of carbohydrates, an acid precursor derivable from an inorganic salt and/or an ammonium salt of one or more polycarboxylic acids, a source of nitrogen, and optionally ammonia.


In another illustrative aspect, the present invention provides a binder based on a mixture of carbohydrates that has a tendency to generate supersaturated aqueous solutions of sugars that do not crystallize out while storing at ambient conditions over a time span of at least 3 days, preferably over a time span of longer than 2 weeks even when in contact with fiberglass.


In another illustrative aspect, the present invention provides for a carbohydrate-based binder wherein the mixture of sugars in the binder has a lower crystallization point than dextrose.


In another illustrative aspect, the present invention provides for a carbohydrate-based binder wherein the mixture of sugars is fructose and dextrose present in high fructose corn syrup (HFCS), which is used as a carbohydrate source.


In another illustrative aspect, the present invention provides for a carbohydrate-based binder which permits close control of the ratio of moisture to binder concentration in a fiberglass product.


In another illustrative aspect, the present invention provides for a carbohydrate-based binder where impurities may be added to mixtures of fructose and dextrose (e.g., mixtures obtained by dissolving fructose and dextrose or by inverting sucrose under known conditions to invert sugar). Such impurities may be dextrins and/or maltodextrins. Another form of impurities can be generated by heating tcarbohydrate solutions to form some degradation products.


In another illustrative aspect, the present invention provides for a carbohydrate-based binder where various additives may be added to improve binder performance and processability. Typical additives known in the art include, but are not necessarily limited to, adhesion promoters, coupling agents, silanes, amino-silanes, silicones, non-aqueous moisturizers, flame retardants, additives to prevent self-heating upon curing, dedusting oils, polymeric additives (e.g., styrene-maleic anhydride copolymers, acrylic copolymers), and cross-linkers (e.g., mono-, di-, and polyfunctional amines, epoxides, isocyanates, blocked isocyanates, hydroxyl-containing compounds, and carboxy-containing compounds, as well as aldehyds and ketones.)


In another illustrative aspect, a method for treating fibers, including non-woven fibers, is enabled that includes contacting mineral fibers (e.g., glass fibers) with a thermally-curable, aqueous binder composition comprising a mixture of carbohydrates, an acid precursor derivable from an inorganic salt and/or an ammonium salt of one or more polycarboxylic acids, a source of nitrogen, and optionally ammonia, as described herein, and effecting removal of most of the water from the thermally-curable, aqueous binder composition in contact with mineral fibers.


In another illustrative aspect, a fiberglass product is described that includes a binder composition, as described herein, in contact with glass fibers, which product may be processed to form one of several types of uncured fiberglass insulation, wherein the glass fibers are present in the range from about 80% to about 99% by weight.


Binder solutions used in accordance with the present invention may be “substantially formaldehyde free”, that is to say that they liberate less than 5 ppm formaldehyde as a result of drying and/or curing (or appropriate tests simulating drying and/or curing). Such binder solutions are preferably “formaldehyde free”, that is the say they liberate less than 1 ppm formaldehyde in such conditions.


Products in accordance with the present invention (for example, uncured fiberglass insulation materials) may be “substantially formaldehyde free;” that is to say that they comprise less than 5 ppm or less than detectable limits of free formaldehyde and/or consist of materials which together comprise less than these amounts of free formaldehyde and/or release levels of formaldehyde in standardized tests adapted to simulate their ordinary use which allows them to be classified as having no or undetectable levels of formaldehyde release. Preferably, such products release less than 10 μg/m3, more preferably less than 5 μg/m3, of formaldehyde during the period of 24-48 hours from the start of testing in accordance with ISO 16000.


Additional features of the present invention will become apparent to those skilled in the art upon consideration of the following detailed description of illustrative embodiments exemplifying the best mode of carrying out the invention as presently perceived.







DETAILED DESCRIPTION

It has been found that binders according to the present invention may have at least equivalent and, in some instances, improved properties compared to, for example, the tri-ammonium citrate-dextrose system of WO 2007/014236 and compared to, for example, the triammonium phosphate-dextrose system of WO 2009/019235. WO 2007/014236 teaches binder systems based, inter alia, on a combination of a carbohydrate (for example, a reducing sugar), ammonia and a polycarboxylic acid and suggests that a Maillard type reaction may form the basis of the curing chemistry. WO 2009/019235 teaches binder systems based, inter alia, on a combination of a carbohydrate (for example, a reducing sugar), an acid precursor derivable from an inorganic salt, and ammonia and suggests that a Maillard type reaction may form the basis of the curing chemistry. It would have been thought that inclusion of a mixture of at least two carbohydrates would not have a significant effect on the properties of the resulting uncured binder, particularly if the carbohydrates are both reducing sugars. It is thus surprising that a mixture of at least two carbohydrates (e.g., dextrose and fructose) should provide improved properties in an otherwise apparently similar binder system.


Use of an acid precursor derivable from an inorganic salt may have significant advantages in terms of cost, availability and ease of handling. The acid precursor derivable from an inorganic salt of the binder solution may comprise a species selected from the group consisting of sulfates, phosphates, nitrates and carbonates. A particular advantage can be achieved by use of one or more inorganic ammonium salts, for example, an ammonium sulfate, an ammonium phosphate or an ammonium carbonate salt. An ammonium salt may provide the or part of the acid precursor and/or the or part of the source of nitrogen and/or the or part of a pH control system. An ammonium nitrate salt may also work; however, ammonium nitrate may oxidise aldehyde groups of the carbohydrate (for example, aldehyde groups in dextrose) and/or require precautions to avoid explosions.


Ammonium sulfate is particularly advantageous but ammonium phosphate may be used in addition to or instead of ammonium sulfate Ammonium phosphate may be monoammonium phosphate, diammonium phosphate or triammonium phosphate; it may be an ammonium hydrogen phosphate. An ammonium carbonate, alone or in combination with the other materials disclosed herein, may also provide good results. The ammonium carbonate may be an ammonium bicarbonate.


The acid precursor, particularly when this consists essentially of inorganic ammonium salt(s), may make up at least 5%, preferably at least 7%, more preferably at least 9% by dry weight of the uncured binder solution; and/or less than 25% or 20%, preferably less than 18%, more preferably less than 16% by dry weight of the uncured binder solution.


The term “consist or consisting essentially of” is intended to limit the scope of a claim to the specified materials or steps and those that do not materially affect the basic and novel characteristic(s) of the claimed invention.


The acid may comprise: a sulfuric acid, a phosphoric acid, a nitric acid or a weak acid.


The binder may comprise between 5% and 25%, preferably 10% to 20%, more preferably 15% to 20% by dry weight of acid precursor (particularly where this is an inorganic ammonium salt) to total carbohydrate (particularly when this is a mixture of reducing sugars).


A carbohydrate-based binder comprising a mixture of carbohydrates, as described herein, may alternatively or in addition contain an ammonium salt of one or more polycarboxylic acid components, where the salt is monobasic or dibasic when the polycarboxylic acid component is a dicarboxylic acid, or where the salt is monobasic, dibasic, or tribasic when the polycarboxylic acid component is a tricarboxylic acid, and so on and so forth.


As used herein, the term “ammonium” includes, but is not limited to, +NH4, +NH3R1 and +NH2R1R2, where R1 and R2 are each independently selected in +NH2R1R2, and where R1 and R2 are selected from alkyl, cycloalkyl, alkenyl, cycloalkenyl, heterocyclyl, aryl, and heteroaryl.


The term “alkyl” refers to a saturated monovalent chain of carbon atoms, which may be optionally branched; the term “cycloalkyl” refers to a monovalent chain of carbon atoms, a portion of which forms a ring; the term “alkenyl” refers to an unsaturated monovalent chain of carbon atoms including at least one double bond, which may be optionally branched; the term “cycloalkenyl” refers to an unsaturated monovalent chain of carbon atoms, a portion of which forms a ring; the term “heterocyclyl” refers to a monovalent chain of carbon and heteroatoms, wherein the heteroatoms are selected from nitrogen, oxygen, and sulfur, a portion of which, including at least one heteroatom, form a ring; the term “aryl” refers to an aromatic mono or polycyclic ring of carbon atoms, such as phenyl, naphthyl, and the like; and the term “heteroaryl” refers to an aromatic mono or polycyclic ring of carbon atoms and at least one heteroatom selected from nitrogen, oxygen, and sulfur, such as pyridinyl, pyrimidinyl, indolyl, benzoxazolyl, and the like. It is to be understood that each of alkyl, cycloalkyl, alkenyl, cycloalkenyl, and heterocyclyl may be optionally substituted with independently selected groups such as alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, carboxylic acid and derivatives thereof, including esters, amides, and nitriles, hydroxy, alkoxy, acyloxy, amino, alkyl and dialkylamino, acylamino, thio, and the like, and combinations thereof It is further to be understood that each of aryl and heteroaryl may be optionally substituted with one or more independently selected substituents, such as halo, hydroxy, amino, alkyl or dialkylamino, alkoxy, alkylsulfonyl, cyano, nitro, and the like.


As used herein, the term “polycarboxylic acid” indicates a dicarboxylic, tricarboxylic, tetracarboxylic, pentacarboxylic, and like monomeric polycarboxylic acids, and anhydrides, and combinations thereof, as well as polymeric polycarboxylic acids, anhydrides, copolymers, and combinations thereof In one aspect, the polycarboxylic acid ammonium salt reactant is sufficiently non-volatile to maximize its ability to remain available for reaction with a mixture of carbohydrates in a Maillard reaction. In another aspect, the polycarboxylic acid ammonium salt reactant may be substituted with other chemical functional groups.


Illustratively, a monomeric polycarboxylic acid may be a dicarboxylic acid, including, but not limited to, unsaturated aliphatic dicarboxylic acids, saturated aliphatic dicarboxylic acids, aromatic dicarboxylic acids, unsaturated cyclic dicarboxylic acids, saturated cyclic dicarboxylic acids, hydroxy-substituted derivatives thereof, and the like. Or, illustratively, the polycarboxylic acid(s) itself may be a tricarboxylic acid, including, but not limited to, unsaturated aliphatic tricarboxylic acids, saturated aliphatic tricarboxylic acids, aromatic tricarboxylic acids, unsaturated cyclic tricarboxylic acids, saturated cyclic tricarboxylic acids, hydroxy-substituted derivatives thereof, and the like. It is appreciated that any such polycarboxylic acids may be optionally substituted, such as with hydroxy, halo, alkyl, alkoxy, and the like. In one variation, the polycarboxylic acid is the saturated aliphatic tricarboxylic acid, citric acid. Other suitable polycarboxylic acids are contemplated to include, but are not limited to, aconitic acid, adipic acid, azelaic acid, butane tetracarboxylic acid dihydride, butane tricarboxylic acid, chlorendic acid, citraconic acid, dicyclopentadiene-maleic acid adducts, diethylenetriamine pentaacetic acid, adducts of dipentene and maleic acid, ethylenediamine tetraacetic acid (EDTA), fully maleated rosin, maleated tall-oil fatty acids, fumaric acid, glutaric acid, isophthalic acid, itaconic acid, maleated rosin oxidized with potassium peroxide to alcohol then carboxylic acid, maleic acid, malic acid, mesaconic acid, biphenol A or bisphenol F reacted via the KOLBE-Schmidt reaction with carbon dioxide to introduce 3-4 carboxyl groups, oxalic acid, phthalic acid, sebacic acid, succinic acid, tartaric acid, terephthalic acid, tetrabromophthalic acid, tetrachlorophthalic acid, tetrahydrophthalic acid, trimellitic acid, trimesic acid, and the like, and anhydrides, and combinations thereof


Illustratively, a polymeric polycarboxylic acid may be an acid, for example, polyacrylic acid, polymethacrylic acid, polymaleic acid, and like polymeric polycarboxylic acids, copolymers thereof, anhydrides thereof, and mixtures thereof Examples of commercially available polyacrylic acids include AQUASET-529 (Rohm & Haas, Philadelphia, Pa., USA), CRITERION 2000 (Kemira, Helsinki, Finland, Europe), NF1 (H. B. Fuller, St. Paul, Minn., USA), and SOKALAN (BASF, Ludwigshafen, Germany, Europe). With respect to SOKALAN, this is a water-soluble polyacrylic copolymer of acrylic acid and maleic acid, having a molecular weight of approximately 4000. AQUASET-529 is a composition containing polyacrylic acid cross-linked with glycerol, also containing sodium hypophosphite as a catalyst. CRITERION 2000 is an acidic solution of a partial salt of polyacrylic acid, having a molecular weight of approximately 2000. With respect to NF1, this is a copolymer containing carboxylic acid functionality and hydroxy functionality, as well as units with neither functionality; NF1 also contains chain transfer agents, such as sodium hypophosphite or organophosphate catalysts.


With respect to the mixture of carbohydrates in the binder described herein, it may include a mixture of two or more reducing sugars. In one aspect, any carbohydrate in said mixture should be sufficiently nonvolatile to maximize its ability to remain available for reaction with the acid precursor derivable from an inorganic salt and/or the polycarboxylic acid ammonium salt. The carbohydrate mixture may include a monosaccharide in its aldose or ketose form, including a triose, a tetrose, a pentose, a hexose, or a heptose; or a polysaccharide; or combinations thereof A carbohydrate may be a reducing sugar, or one that yields one or more reducing sugars in situ under thermal curing conditions. For example, when a triose serves as the carbohydrate in combination with other reducing sugars and/or a polysaccharide, an aldotriose sugar or a ketotriose sugar may be utilized, such as glyceraldehyde and dihydroxyacetone, respectively. When a tetrose serves as the carbohydrate in combination with other reducing sugars and/or a polysaccharide, aldotetrose sugars, such as erythrose and threose; and ketotetrose sugars, such as erythrulose, may be utilized. When a pentose serves as the carbohydrate in combination with other reducing sugars and/or a polysaccharide, aldopentose sugars, such as ribose, arabinose, xylose, and lyxose; and ketopentose sugars, such as ribulose, arabulose, xylulose, and lyxulose, may be utilized. When a hexose serves as the carbohydrate in combination with other reducing sugars and/or a polysaccharide, aldohexose sugars, such as glucose (i.e., dextrose), mannose, galactose, allose, altrose, talose, gulose, and idose; and ketohexose sugars, such as fructose, psicose, sorbose and tagatose, may be utilized. When a heptose serves as the carbohydrate reactant in combination with other reducing sugars and/or a polysaccharide, a ketoheptose sugar such as sedoheptulose may be utilized.


One or more aldotriose sugars may be used in combination with one or more ketotriose sugars. One or more aldotetrose sugars may be used in combination with one or more ketotetrose sugars. One or more aldopentose sugars may be used in combination with one or more ketopentose sugars. One or more aldohexose sugars may be used in combination with one or more ketohexose sugars.


One or more aldotriose sugars may be used in combination with one or more ketotetrose sugars. One or more aldopentose sugars may be used in combination with one or more ketohexose sugars. One or more aldohexose sugars may be used in combination with one or more ketopentose sugars. One or more ketohexose sugars may be used in combination with one or more aldotetrose sugars. And so on and so forth.


Other stereoisomers of such carbohydrates not known to occur naturally are also contemplated to be useful in preparing the binder compositions as described herein. When a polysaccharide serves as a carbohydrate in combination with monosaccharides, sucrose, lactose, maltose, starch, and cellulose may be utilized.


Furthermore, the mixture of carbohydrates in the binder described herein may be used in combination with one or more non-carbohydrate polyhydroxy reactant. Examples of non-carbohydrate polyhydroxy reactants which can be used in combination with a mixture of carbohydrates include, but are not limited to, trimethylolpropane, glycerol, pentaerythritol, polyvinyl alcohol, partially hydrolyzed polyvinyl acetate, fully hydrolyzed polyvinyl acetate, and mixtures thereof In one aspect, the non-carbohydrate polyhydroxy reactant is sufficiently nonvolatile to maximize its ability to remain available for reaction with the acid precursor derivable from an inorganic acid and/or with a monomeric or polymeric polycarboxylic acid ammonium salt. It is appreciated that the hydrophobicity of the non-carbohydrate polyhydroxy reactant may be a factor in determining the physical properties of a binder prepared as described herein.


Commercial quality high fructose corn syrup, HFCS 42, which contains 42% fructose, may be used as the mixture of carbohydrates for the binders described herein. In one illustrative embodiment, the binder described herein may be derived essentially from HFCS and an inorganic ammonium salt in aqueous solution. In another illustrative embodiment, the binder described herein may alternatively or also comprise an ammonium salt of a polycarboxylic acid, particularly a dicarboxylic acid or tricarboxylic acid, preferably citric acid.


Binders which comprise or consist essentially of the components described herein may include additives, for example, additives selected from: silanes, mineral oils, coupling agents, silicones or siloxanes (particularly for water repellency), silicon containing compounds, surfactants, hydrophilic additives, hydrophobic additives, waxes, substances useful for controlling the pH (e.g. ammonium hydroxide) and ammonia. Ammonium hydroxide when used, and indeed other additives, may provide the and/or an additional source of nitrogen. Preferably, the total quantity of additives (excluding ammonia) is less than 5% by weight (excluding the weight of water present), more preferably less than 3% or less than 2% by weight. Particularly for mineral fiber products, it is preferred to include a silane as an additive. The binder and/or binder solution may comprise at least 0.1% and/or less than 1% of a silane by dry weight. The silane may be amino substituted; it may be a silyl ether and it is believed that its presence may significantly improve the long term strength of the binder, particularly after weathering.


Preferences for the pH of the binder are: preferred, pH≥7; more preferred, pH≥8; and most preferred, pH≥9, at least in the state in which the binder is applied to a material to be bound and/or recovered in a waste water recuperation system. Such a neutral or alkaline pH of the binder may alleviate problems of corrosion of manufacturing equipment which have been encountered with some essentially acidic prior art binder systems. Such prior art binders include binders consisting essentially of polyacrylic acids or polymeric polycarboxylic acids. One particular advantage of the present invention is thus the use of a binder system that can operate in such neutral or alkaline conditions. When cured, the binder may become acidic during the curing process. However, equipment corrosion considerations are less significant in this case due to the minimal contact between the manufacturing equipment and the binder when in this state. The pH of the binder may be less than or equal to 13, preferably less than or equal to 12, 11 or 10. A preferred pH may be in the range of 7.5 to 9.5, particularly 8 to 9. Binder which has been applied to the material to be bound and is subsequently dissolved in water may have a pH of greater than 6.


It is preferred to arrange the pH of the binder solution at an appropriate level to prevent precipitation of its constituents and particularly to ensure that the acid precursor derivable from an inorganic salt remains in solution. This is particularly the case where ammonium phosphate provides the acid precursor. Better dry and/or weathered strengths and/or more homogeneous products may be achieved by using homogeneous binder solutions comprising ammonium salt acid precursors which are free from precipitates, particularly when ammonium phosphate is used and the binder solution is free from phosphate precipitates.


The binder composition may be provided in the form of an aqueous solution; it may contain free ammonia or excess ammonia in solution. A neutral or alkaline pH of the binder may be generated by an excess of alkaline groups compared with acid groups present in the binder solution, for example, due partially or substantially to the presence of ammonia in the solution. Additional ammonia may be added to the binder solution, for example 0.2%-1% by weight, or indeed more; this may help to keep a wash water system alkaline over the long term, particularly for the manufacture of mineral wool insulation.


In the case or mineral wool fibers particularly for thermal insulation products, when binder solution is sprayed onto hot mineral wool fibers just after they have been formed, the residual heat of the mineral wool fibers may cause a significant portion of any water in the binder solution to evaporate. Consequently, the mineral wool fibers which are then collected to form a bat may have binder present on them in the form of a sticky, viscous or tacky liquid. This may facilitate bonding between individual fibers via the binder.


One of the many advantages of this binder system is that it is applied, for example, by being sprayed onto mineral wool fibers, in a substantially unreacted state. The ability to apply the binder solution in a substantially unreacted state may alleviate problems associated with pre-reacting the binder components in solution which have been encountered with some prior art binder systems in which the components are pre-reacted. Such prior art binders include binders consisting essentially of pre-reacted polymers or resins which are applied to the materials to be bound. With substantially unreacted binder present in the form of a sticky, viscous or tacky liquid on the material to be bound, the reaction between the binder components may occur in a substantially dry state. One may describe the reaction as a bulk polymerization because it is occurring without the benefit of a solvent. A particular advantage of the present invention is thus the use of a binder system that can polymerize in a substantially dry state or through a bulk polymerization.


Mineral fibers used in the context of the invention may be formed by internal or external spinning. They may have a temperature in the range 20° C. to 200° C., generally 30° C. to 100° C. or 150° C., when sprayed with the binder solution. The quantity of binder solution sprayed may be used with or without additional water sprays to assist in cooling the mineral fibers to a desired temperature between their formation and their collection to form a batt.


A particular advantage of using ammonia in solution to control the pH of the binder solution applied to the mineral fibers is that at least part of the ammonia of binder solution that sticks to the fibers may flash off due to the residual heat of the mineral wool fibers. Consequently, the binder solution that coats the fibers may have a lower pH than the binder solution sprayed.


The present invention extends to a method of manufacturing a mineral fiber thermal insulation product comprising the sequential steps of: forming mineral fibers from a molten mineral mixture; spraying a substantially formaldehyde free binder solution on to the mineral fibers, the binder solution comprising: a mixture of carbohydrates (particularly a mixture of reducing sugars), an acid precursor derivable from an inorganic salt and/or an ammonium salt of a polycarboxylic acid, and a source of nitrogen; and collecting the mineral fibers to which the binder solution has been applied to form a uncured batt of mineral fibers. Wash water may be sprayed on to mineral fibers between their formation and their collection to form a bat, at least a part of the wash water having been sprayed on mineral fibers and subsequently returned to a wash water system to be reused as wash water. The binder solution may comprise wash water.


The binder may eventually be cured, for example in a curing oven; it may form a thermoset binder. In its cured form, the binder may: comprise melanoidins; and/or be thermoset; and/or be water insoluble or substantially water insoluble. The binder solution may be substantially colorless or white to off-white; upon curing, the binder may take on a dark color, particularly a dark brown color. The cured product may be dark in color, particularly dark brown in color. The binder may be free of proteins; it may be free of cellulosic feedstock. One of the many advantages of this binder system is that the extent of curing can be determined by the color. Substantially dehydrated binder appears white or off-white. Progressively cured to a greater extent, the binder appears progressively darker in color (a darker shade of brown). When applied to mineral fibers, the extent to which the mineral wool insulation has cured can be determined by its color.


When applied to the material to be bound and/or prior to curing, the binder may be free or substantially free of melanoidins and/or other reaction products derived from curing. Curing of the binder may produce glucosylamine, particularly as an intermediate product. Consequently, a cured or particularly a partially cured product may comprise glucosylamine The reaction of the binder upon curing may be essentially a Maillard type reaction as described for example in WO2007/14236. The binder may comprise polymerization products of a mixture that comprises a mixture of reducing sugars and a material selected from the group consisting of ammonium sulfate, ammonium phosphate, ammonium nitrate and ammonium carbonate.


The binder solution may be formulated by combining: a mixture of reducing sugar carbohydrates (e.g., provided by HFCS), an acid precursor derivable from an inorganic salt (preferably an ammonium sulfate or ammonium phosphate) and/or an ammonium salt of a polycarboxylic acid, a source of nitrogen, and water. The formulation may comprise optional or additional ammonia provided in the form of an aqueous ammonia solution. The water may comprise wash water or recycled process water.


Forming the binder solution from a mixture of carbohydrates, an acid precursor comprising an inorganic ammonium salt and/or an ammonium salt of a polycarboxylic acid provides one particular advantageous preparation method. This may be achieved in a simple mixing chamber which may be open and/or at atmospheric pressure. The mixture of carbohydrates and the acid precursor and/or the ammonium salt may be added in powder or liquid form. The preparation is preferably carried out at room temperature. Preferably it is not necessary to supply heat to prepare the binder solution; nevertheless, the binder solution may be heated during its preparation, for example to a temperature with the range 20° C. to 80° C., particularly where this facilitates dissolving and/or mixing of its ingredients.


The binder solution, particularly in the state applied to the material to be bound, may comprise: at least 5% 10%, 15% or 18% solids and/or less than 70% or 60% (particularly in the case of wood board applications) or less than 50%, 40% or 20% solids (particularly in the case of mineral fiber insulation applications) particularly determined as bake out solids by weight after drying at 140° C. for 2 hours.


The collection of loose matter bound together by means of the binders described herein may comprise materials selected from: fibers, fibrous materials, mineral fibers, glass fibers, stone wool fibers, cellulosic fibers (including wood fibers, wood shavings, wood particles and sawdust), wood veneers, facings, wood facings, particles, woven or non-woven materials, loosely assembled materials, woven or non-woven materials.


The loose matter may be shaped and/or dimensioned and/or molded with the aid of the binder. The material produced may be selected from: a thermal insulation material, a mineral fiber product, a wood board product (including chip board, orientated strand board, particle board, medium density fiber board, wood facing products), foundry sands.


The matter to be bound may be at a temperature in the range 20° C. to 100° C. when the binder is applied. The binder solution, particularly when applied to the loose matter, may have a viscosity appropriate for application by spraying or pouring. Its viscosity at 20° C. may be less than about 1.5 Pas, preferably less than about 1×10−2 Pas, and/or greater than about 2×10−4 Pas, preferably greater than about 5×10−4 Pas.


EXAMPLES

The following examples illustrate specific embodiments in further detail. These examples are provided for illustrative purposes only and should not be construed as limiting the invention or the inventive concept to any particular physical configuration in any way.


An uncured binder composition was prepared as HFCS 42:Ammonium Sulfate=76.4:16 based on dry solids. HFCS 42 is commercial quality High Fructose Corn Syrup with 42% Fructose concentration. The preferred moisture content of an uncured fiberglass insulation product is 0.5% to 4%.


Example 1: For a fiberglass insulation product with 7% LOI after cure, the free moisture content of the uncured fiberglass insulation product is in the range of 0.5% to 7%.


Example 2: For a fiberglass insulation product with 15% LOI after cure, the free moisture content of the uncured fiberglass insulation product is in the range of 1% to 7%.


In order to demonstrate the supersaturated nature of a carbohydrate-based binder of the present invention, a preferred uncured fiberglass insulation product from Example 2 has 5% free moisture.


The uncured fiberglass insulation product of Example 2 with an LOI of 15% contains approximately 21.5% binder solids of HFCS 42:Ammonium Sulfate=76.4:16. This corresponds to 17.8% HFCS and 3.7% Ammonium Sulfate based on dry weight of uncured product. Said uncured product has a free moisture concentration of 2.5%. The ratio of Ammonium Sulfate to free moisture is 3.7:2.5. The ratio of HFCS 42:free moisture is 17.8:2.5 At ambient temperatures (e.g., 20° C.) these ratios are beyond the solubility ratios of HFCS:Water of approximately 17.8:7.7 and HFCS:Ammonium Sulfate=3.7:5.


Molding of 9-month-old uncured fiberglass insulation made with HFCS/AS (Cured binder LOI: 15-17%; Moisture of Uncured: 1.5%-3%; product stored in PE bag at 15° C.-24° C.) was associated with essentially no crystallization, and the uncured insulation product was soft, showed good recovery, and processed well. This is in contrast to Dextrose/AS migrating and crystallizing out within 2 weeks, which illustrates an economic advantage of using HFCS.

Claims
  • 1. A composition comprising an uncured binder disposed on mineral fibers, wherein the uncured binder consists of an aqueous mixture of (a) at least two reducing sugars comprising 1) at least one aldohexose sugar selected from the group consisting of dextrose, mannose, galactose, allose, altrose, talose, gulose, and idose; and 2) at least one ketohexose sugar selected from the group consisting of fructose, psicose, sorbose and tagatose, wherein the mixture has a lower crystallization point than a carbohydrate mixture consisting of dextrose; and (b) an acid precursor derivable from an inorganic salt selected from the group consisting of ammonium sulfate salts, ammonium phosphate salts, ammonium nitrate salts, ammonium carbonate salts and combinations thereof and/or (c) an ammonium salt of a polycarboxylic acid; optionally (d) a silicon-containing compound; and optionally (e) a corrosion inhibitor.
  • 2. The composition of claim 1, wherein the inorganic salt is selected from the group consisting of ammonium sulfate salts, ammonium phosphate salts, ammonium carbonate salts, and combinations thereof.
  • 3. The composition of claim 1, wherein the polycarboxylic acid is selected from the group consisting of unsaturated aliphatic polycarboxylic acids, saturated aliphatic polycarboxylic acids, aromatic polycarboxylic acids, unsaturated cyclic polycarboxylic acids, saturated cyclic polycarboxylic acids, and combinations thereof.
  • 4. The composition of claim 1, wherein the silicon-containing compound is selected from the group consisting of gamma-aminopropyltriethoxysilane, gamma-glycidoxypropyltrimethoxysilane, and mixtures thereof.
  • 5. The composition of claim 1, wherein the corrosion inhibitor is capable of decreasing the corrosivity of the composition.
  • 6. The composition of claim 5, wherein the corrosion inhibitor is selected from the group consisting of dedusting oil, monoammonium phosphate, sodium metasilicate pentahydrate, and melamine.
  • 7. The composition of claim 1, wherein the composition is a fiberglass insulation product.
  • 8. The composition of claim 1, wherein the mineral fibers comprise fibers selected from glass fibers and stone wool fibers.
  • 9. The composition of claim 8, wherein the mineral fibers comprise glass fibers.
  • 10. The composition of claim 1, wherein the mixture of at least two reducing sugars is provided as high fructose corn syrup (HFCS).
  • 11. The composition of claim 1, wherein the binder has a moisture content of 1.5-3%.
  • 12. The composition of claim 1, wherein the binder has a pH of 7.5-9.5.
  • 13. The composition of claim 1, wherein the mineral fibers comprise glass fibers at a compositional concentration of 80-99% by weight.
  • 14. The composition of claim 1, wherein the binder compriscs has 5-25% by dry weight of an acid precursor derivable from an inorganic salt selected from the group consisting of ammonium sulfate salts, ammonium phosphate salts, ammonium nitrate salts, ammonium carbonate salts and combinations thereof.
  • 15. The composition of claim 1, wherein the binder has 10-20% by dry weight of an acid precursor derivable from an inorganic salt selected from the group consisting of ammonium sulfate salts, ammonium phosphate salts, ammonium nitrate salts, ammonium carbonate salts and combinations thereof.
  • 16. The composition of claim 1, wherein the aqueous mixture is a viscous or tacky liquid.
CROSS-REFERENCE TO RELATED APPLICATION

This application is a U.S. national counterpart application of International Application Serial No. PCT/US2015/014786, filed Feb. 6, 2015, under 35 U.S.C. § 371, which claims priority under 35 U.S.C.§ 119(e) to U.S. Provisional Application Serial No. 61/937,110, filed Feb. 7, 2014, the disclosures of which are hereby incorporated herein by reference.

PCT Information
Filing Document Filing Date Country Kind
PCT/US2015/014786 2/6/2015 WO 00
Publishing Document Publishing Date Country Kind
WO2015/120252 8/13/2015 WO A
US Referenced Citations (477)
Number Name Date Kind
1801052 Meigs Apr 1931 A
1801053 Meigs Apr 1931 A
1886353 Novotny et al. Nov 1932 A
1902948 Castle Mar 1933 A
1964263 Krenke Jun 1934 A
2198874 Leighton Apr 1940 A
2215825 Wallace et al. Sep 1940 A
2261295 Schlack Nov 1941 A
2362086 Eastes et al. Nov 1944 A
2371990 Hanford Mar 1945 A
2392105 Sussman Jan 1946 A
2442989 Sussman Jun 1948 A
2500665 Courtright Mar 1950 A
2518956 Sussman Aug 1950 A
2875073 Gogek Feb 1959 A
2894920 Ramos Jul 1959 A
2965504 Gogek Dec 1960 A
3038462 Bohdan Jun 1962 A
3138473 Floyd et al. Jun 1964 A
3222243 Gaston et al. Dec 1965 A
3231349 Stalego Jan 1966 A
3232821 Banks et al. Feb 1966 A
3297419 Eyre, Jr. Jan 1967 A
3513001 Woodhead et al. May 1970 A
3551365 Matalon Dec 1970 A
3784408 Jaffe et al. Jan 1974 A
3791807 Etzel et al. Feb 1974 A
3802897 Voigt et al. Apr 1974 A
3809664 Burr et al. May 1974 A
3826767 Hoover et al. Jul 1974 A
3856606 Fan et al. Dec 1974 A
3867119 Takeo et al. Feb 1975 A
3907724 Higginbottom Sep 1975 A
3911048 Vargiu et al. Oct 1975 A
3919134 Higginbottom Nov 1975 A
3922466 Bell et al. Nov 1975 A
3955031 Jones et al. May 1976 A
3956204 Higginbottom May 1976 A
3961081 McKenzie Jun 1976 A
3971807 Brack Jul 1976 A
4014726 Fargo Mar 1977 A
4028290 Reid Jun 1977 A
4048127 Gibbons et al. Sep 1977 A
4054713 Sakaguchi et al. Oct 1977 A
4085076 Gibbons et al. Apr 1978 A
4097427 Aitken et al. Jun 1978 A
4107379 Stofko Aug 1978 A
4109057 Nakamura et al. Aug 1978 A
4144027 Habib Mar 1979 A
4148765 Nelson Apr 1979 A
4183997 Stofko Jan 1980 A
4184986 Krasnobajew et al. Jan 1980 A
4186053 Krasnobajew et al. Jan 1980 A
4201247 Shannon May 1980 A
4201857 Krasnobajew et al. May 1980 A
4217414 Walon Aug 1980 A
4233432 Curtis, Jr. Nov 1980 A
4246367 Curtis, Jr. Jan 1981 A
4259190 Fahey Mar 1981 A
4265963 Matalon May 1981 A
4278573 Tessler Jul 1981 A
4296173 Fahey Oct 1981 A
4301310 Wagner Nov 1981 A
4310585 Shannon Jan 1982 A
4322523 Wagner Mar 1982 A
4330443 Rankin May 1982 A
4333484 Keritsis Jun 1982 A
4357194 Stofko Nov 1982 A
4361588 Herz Nov 1982 A
4379101 Smith Apr 1983 A
4393019 Geimer Jul 1983 A
4396430 Matalon Aug 1983 A
4400496 Butler et al. Aug 1983 A
4464523 Neigel et al. Aug 1984 A
4506684 Keritsis Mar 1985 A
4520143 Jellinek May 1985 A
4524164 Viswanathan et al. Jun 1985 A
4631226 Jellinek Dec 1986 A
4654259 Stofko Mar 1987 A
4668716 Pepe et al. May 1987 A
4692478 Viswanathan et al. Sep 1987 A
4714727 Hume, III Dec 1987 A
4720295 Bronshtein Jan 1988 A
4734996 Kim et al. Apr 1988 A
4754056 Ansel et al. Jun 1988 A
4761184 Markessini Aug 1988 A
4780339 Lacourse et al. Oct 1988 A
4828643 Newman et al. May 1989 A
4845162 Schmitt et al. Jul 1989 A
4906237 Johansson et al. Mar 1990 A
4912147 Pfoehler et al. Mar 1990 A
4918861 Carpenter et al. Apr 1990 A
4923980 Blomberg May 1990 A
4950444 Deboufie et al. Aug 1990 A
4988780 Das et al. Jan 1991 A
4992519 Mukherjee Feb 1991 A
5001202 Denis et al. Mar 1991 A
5013405 Izard May 1991 A
5032431 Conner et al. Jul 1991 A
5037930 Shih Aug 1991 A
5041595 Yang et al. Aug 1991 A
5089342 Dhein et al. Feb 1992 A
5095054 Lay et al. Mar 1992 A
5106615 Dikstein Apr 1992 A
5114004 Isono et al. May 1992 A
5123949 Thiessen Jun 1992 A
5124369 Vandichel et al. Jun 1992 A
5128407 Layton et al. Jul 1992 A
5143582 Arkens et al. Sep 1992 A
5151465 Le-Khac Sep 1992 A
5167738 Bichot et al. Dec 1992 A
5198492 Stack Mar 1993 A
5217741 Kawachi et al. Jun 1993 A
5218048 Abe et al. Jun 1993 A
5240498 Matalon et al. Aug 1993 A
5244474 Lorcks et al. Sep 1993 A
5278222 Stack Jan 1994 A
5300144 Adams Apr 1994 A
5300192 Hansen et al. Apr 1994 A
5308896 Hansen et al. May 1994 A
5318990 Strauss Jun 1994 A
5336753 Jung et al. Aug 1994 A
5336755 Pape Aug 1994 A
5336766 Koga et al. Aug 1994 A
5340868 Strauss et al. Aug 1994 A
5352480 Hansen et al. Oct 1994 A
5367849 Bullock Nov 1994 A
5371194 Ferretti Dec 1994 A
5387665 Misawa et al. Feb 1995 A
5389716 Graves Feb 1995 A
5393849 Srinivasan et al. Feb 1995 A
5416139 Zeiszler May 1995 A
5421838 Gosset et al. Jun 1995 A
5424418 Duflot Jun 1995 A
5434233 Kiely et al. Jul 1995 A
5447977 Hansen et al. Sep 1995 A
5470843 Stahl et al. Nov 1995 A
5480973 Goodlad et al. Jan 1996 A
5492756 Seale et al. Feb 1996 A
5498662 Tanaka et al. Mar 1996 A
5503920 Alkire et al. Apr 1996 A
5534612 Taylor et al. Jul 1996 A
5536766 Seyffer et al. Jul 1996 A
5538783 Hansen et al. Jul 1996 A
5543215 Hansen et al. Aug 1996 A
5545279 Hall et al. Aug 1996 A
5547541 Hansen et al. Aug 1996 A
5547745 Hansen et al. Aug 1996 A
5550189 Qin et al. Aug 1996 A
5554730 Woiszwillo et al. Sep 1996 A
5562740 Cook et al. Oct 1996 A
5571618 Hansen et al. Nov 1996 A
5578678 Hartmann et al. Nov 1996 A
5580856 Prestrelski et al. Dec 1996 A
5582682 Ferretti Dec 1996 A
5583193 Aravindakshan et al. Dec 1996 A
5589256 Hansen et al. Dec 1996 A
5589536 Golino et al. Dec 1996 A
5607759 Hansen et al. Mar 1997 A
5608011 Eck et al. Mar 1997 A
5609727 Hansen et al. Mar 1997 A
5614570 Hansen et al. Mar 1997 A
5620940 Birbara et al. Apr 1997 A
5621026 Tanaka et al. Apr 1997 A
5633298 Arfaei et al. May 1997 A
5641561 Hansen et al. Jun 1997 A
5643978 Darwin et al. Jul 1997 A
5645756 Dubin et al. Jul 1997 A
5660904 Andersen et al. Aug 1997 A
5661213 Arkens et al. Aug 1997 A
5670585 Taylor et al. Sep 1997 A
5672418 Hansen et al. Sep 1997 A
5672659 Shalaby et al. Sep 1997 A
5690715 Schiwek Nov 1997 A
5691060 Levy Nov 1997 A
5693411 Hansen et al. Dec 1997 A
5719092 Arrington Feb 1998 A
5719228 Taylor et al. Feb 1998 A
5733624 Syme et al. Mar 1998 A
5756580 Natori et al. May 1998 A
5763524 Arkens et al. Jun 1998 A
5788243 Harshaw et al. Aug 1998 A
5788423 Perkins Aug 1998 A
5807364 Hansen Sep 1998 A
5855987 Margel et al. Jan 1999 A
5863985 Shalaby et al. Jan 1999 A
5885337 Nohr et al. Mar 1999 A
5895804 Lee et al. Apr 1999 A
5905115 Luitjes et al. May 1999 A
5916503 Rettenbacher Jun 1999 A
5919528 Huijs et al. Jul 1999 A
5919831 Philipp Jul 1999 A
5922403 Tecle Jul 1999 A
5925722 Exner et al. Jul 1999 A
5929184 Holmes-Farley et al. Jul 1999 A
5929196 Kissel et al. Jul 1999 A
5932344 Ikemoto et al. Aug 1999 A
5932665 DePorter et al. Aug 1999 A
5932689 Arkens et al. Aug 1999 A
5942123 McArdle Aug 1999 A
5954869 Elfersy et al. Sep 1999 A
5977224 Cheung et al. Nov 1999 A
5977232 Arkens et al. Nov 1999 A
5981719 Woiszwillo et al. Nov 1999 A
5983586 Berdan, II et al. Nov 1999 A
5990216 Cai et al. Nov 1999 A
5993709 Bonomo et al. Nov 1999 A
6022615 Rettenbacher Feb 2000 A
6067821 Jackson et al. May 2000 A
6071549 Hansen Jun 2000 A
6071994 Hummerich et al. Jun 2000 A
6072086 James et al. Jun 2000 A
6077883 Taylor et al. Jun 2000 A
6090925 Woiszwillo et al. Jul 2000 A
6114033 Ikemoto et al. Sep 2000 A
6114464 Reck et al. Sep 2000 A
6133347 Vickers, Jr. et al. Oct 2000 A
6136916 Arkens et al. Oct 2000 A
6139619 Zaretskiy et al. Oct 2000 A
6143243 Gershun et al. Nov 2000 A
6171444 Nigam Jan 2001 B1
6171654 Salsman et al. Jan 2001 B1
6180037 Andersen et al. Jan 2001 B1
6194512 Chen et al. Feb 2001 B1
6210472 Kwan et al. Apr 2001 B1
6221958 Shalaby et al. Apr 2001 B1
6221973 Arkens et al. Apr 2001 B1
6231721 Quick et al. May 2001 B1
6274661 Chen et al. Aug 2001 B1
6281298 Papsin, Jr. Aug 2001 B1
6299677 Johnson et al. Oct 2001 B1
6299936 Reck et al. Oct 2001 B1
6307732 Tsubaki et al. Oct 2001 B1
6310227 Sarama et al. Oct 2001 B1
6313102 Colaco et al. Nov 2001 B1
6319683 James et al. Nov 2001 B1
6331350 Taylor et al. Dec 2001 B1
6331513 Zaid et al. Dec 2001 B1
6340411 Hansen et al. Jan 2002 B1
6348530 Reck et al. Feb 2002 B1
6365079 Winkler et al. Apr 2002 B1
6372077 Tecle Apr 2002 B1
6379739 Formanek et al. Apr 2002 B1
6379814 Dupre et al. Apr 2002 B1
6395856 Petty et al. May 2002 B1
6403665 Sieker et al. Jun 2002 B1
6407225 Mang et al. Jun 2002 B1
6410036 De Rosa et al. Jun 2002 B1
6440204 Rogols et al. Aug 2002 B1
6441122 DeMott et al. Aug 2002 B1
6461553 Hansen et al. Oct 2002 B1
6468442 Bytnar Oct 2002 B2
6468730 Fujiwara et al. Oct 2002 B2
6469120 Elfersy et al. Oct 2002 B1
6475552 Shah et al. Nov 2002 B1
6482875 Lorenz et al. Nov 2002 B2
6495656 Haile et al. Dec 2002 B1
6521339 Hansen et al. Feb 2003 B1
6525009 Sachdev et al. Feb 2003 B2
6538057 Wildburg et al. Mar 2003 B1
6547867 Rogols et al. Apr 2003 B2
6555616 Helbing et al. Apr 2003 B1
6559302 Shah et al. May 2003 B1
6562267 Hansen et al. May 2003 B1
6596103 Hansen et al. Jul 2003 B1
6613378 Erhan et al. Sep 2003 B1
6638882 Helbing et al. Oct 2003 B1
6638884 Quick et al. Oct 2003 B2
6699945 Chen et al. Mar 2004 B1
6706853 Stanssens et al. Mar 2004 B1
6719862 Quick et al. Apr 2004 B2
6730730 Hansen et al. May 2004 B1
6753361 Kroner et al. Jun 2004 B2
6818694 Hindi et al. Nov 2004 B2
6821547 Shah et al. Nov 2004 B2
6852247 Bytnar Feb 2005 B2
6858074 Anderson et al. Feb 2005 B2
6861495 Barsotti et al. Mar 2005 B2
6864044 Ishikawa et al. Mar 2005 B2
6878800 Husemoen et al. Apr 2005 B2
6884849 Chen et al. Apr 2005 B2
6955844 Tagge et al. Oct 2005 B2
6962714 Hei et al. Nov 2005 B2
6989171 Portman Jan 2006 B2
6992203 Trusovs Jan 2006 B2
7018490 Hansen et al. Mar 2006 B2
7029717 Ojima et al. Apr 2006 B1
7067579 Taylor et al. Jun 2006 B2
7083831 Koch et al. Aug 2006 B1
7090745 Beckman et al. Aug 2006 B2
7141626 Rodrigues et al. Nov 2006 B2
7144474 Hansen et al. Dec 2006 B1
7195792 Boston et al. Mar 2007 B2
7201778 Smith et al. Apr 2007 B2
7201825 Dezutter et al. Apr 2007 B2
7202326 Kuroda et al. Apr 2007 B2
7241487 Taylor et al. Jul 2007 B2
7458235 Beaufils et al. Dec 2008 B2
7514027 Horres et al. Apr 2009 B2
7655711 Swift et al. Feb 2010 B2
7772347 Swift et al. Aug 2010 B2
7795354 Srinivasan et al. Sep 2010 B2
7803879 Srinivasan et al. Sep 2010 B2
7807771 Swift et al. Oct 2010 B2
7842382 Helbing Nov 2010 B2
7854980 Jackson et al. Dec 2010 B2
7883693 Sehl et al. Feb 2011 B2
7888445 Swift et al. Feb 2011 B2
7947765 Swift et al. May 2011 B2
8114210 Hampson et al. Feb 2012 B2
8182648 Swift et al. May 2012 B2
8211923 Wagner et al. Jul 2012 B2
8372900 Shooshtari et al. Feb 2013 B2
8377564 Shooshtari et al. Feb 2013 B2
8501838 Jackson et al. Aug 2013 B2
8597532 Jaffrennou et al. Dec 2013 B2
8680224 Zhang et al. Mar 2014 B2
8691934 Helbing, et al. Apr 2014 B2
8900495 Pacorel et al. Dec 2014 B2
20010017427 Rosthauser et al. Aug 2001 A1
20010046824 Nigam Nov 2001 A1
20020000100 Burg et al. Jan 2002 A1
20020025435 Hansen et al. Feb 2002 A1
20020026025 Kuo et al. Feb 2002 A1
20020028857 Holy Mar 2002 A1
20020032253 Lorenz et al. Mar 2002 A1
20020042473 Trollsas et al. Apr 2002 A1
20020091185 Taylor et al. Jul 2002 A1
20020096278 Foster et al. Jul 2002 A1
20020123598 Sieker et al. Sep 2002 A1
20020130439 Kroner et al. Sep 2002 A1
20020161108 Schultz et al. Oct 2002 A1
20020197352 Portman Dec 2002 A1
20030005857 Minami et al. Jan 2003 A1
20030040239 Toas et al. Feb 2003 A1
20030044513 Shah et al. Mar 2003 A1
20030066523 Lewis et al. Apr 2003 A1
20030071879 Swenson Apr 2003 A1
20030116294 Kehrer et al. Jun 2003 A1
20030134945 Capps Jul 2003 A1
20030148084 Trocino Aug 2003 A1
20030153690 Husemoen et al. Aug 2003 A1
20030185991 Wigger et al. Oct 2003 A1
20030203117 Bartkowiak et al. Oct 2003 A1
20040002567 Chen et al. Jan 2004 A1
20040019168 Soerens et al. Jan 2004 A1
20040024170 Husemoen et al. Feb 2004 A1
20040033269 Hei et al. Feb 2004 A1
20040033747 Miller et al. Feb 2004 A1
20040034154 Tutin et al. Feb 2004 A1
20040038017 Tutin et al. Feb 2004 A1
20040048531 Belmares et al. Mar 2004 A1
20040077055 Fosdick et al. Apr 2004 A1
20040079499 Dezutter et al. Apr 2004 A1
20040087024 Bellocq et al. May 2004 A1
20040087719 Rautschek et al. May 2004 A1
20040122166 O'Brien-Bernini et al. Jun 2004 A1
20040131874 Tutin et al. Jul 2004 A1
20040144706 Beaufils et al. Jul 2004 A1
20040152824 Dobrowolski Aug 2004 A1
20040161993 Tripp et al. Aug 2004 A1
20040209851 Nelson et al. Oct 2004 A1
20040213930 Halabisky Oct 2004 A1
20040220368 Li et al. Nov 2004 A1
20040249066 Heinzman et al. Dec 2004 A1
20040254285 Rodrigues et al. Dec 2004 A1
20040260082 Van Der Wilden et al. Dec 2004 A1
20050001198 Bytnar Jan 2005 A1
20050017394 Hochsmann et al. Jan 2005 A1
20050027283 Richard et al. Feb 2005 A1
20050033037 Trusovs Feb 2005 A1
20050048212 Clamen et al. Mar 2005 A1
20050059770 Srinivasan et al. Mar 2005 A1
20050171085 Pinto et al. Aug 2005 A1
20050196421 Hunter et al. Sep 2005 A1
20050202224 Helbing Sep 2005 A1
20050208852 Weber Sep 2005 A1
20050215153 Cossement et al. Sep 2005 A1
20050245669 Clungeon et al. Nov 2005 A1
20050275133 Cabell et al. Dec 2005 A1
20050288479 Kuroda et al. Dec 2005 A1
20060005580 Espiard et al. Jan 2006 A1
20060009569 Charbonneau et al. Jan 2006 A1
20060044302 Chen Mar 2006 A1
20060099870 Garcia et al. May 2006 A1
20060111480 Hansen et al. May 2006 A1
20060124538 Morcrette et al. Jun 2006 A1
20060135433 Murray et al. Jun 2006 A1
20060141177 Ligtenberg et al. Jun 2006 A1
20060179892 Horres et al. Aug 2006 A1
20060188465 Perrier et al. Aug 2006 A1
20060198954 Frechem et al. Sep 2006 A1
20060231487 Bartley et al. Oct 2006 A1
20060252855 Pisanova et al. Nov 2006 A1
20060281622 Maricourt et al. Dec 2006 A1
20070006390 Clamen et al. Jan 2007 A1
20070009582 Madsen et al. Jan 2007 A1
20070027281 Michl et al. Feb 2007 A1
20070039520 Crews et al. Feb 2007 A1
20070082983 Crews et al. Apr 2007 A1
20070123679 Swift et al. May 2007 A1
20070123680 Swift et al. May 2007 A1
20070129522 Burckhardt et al. Jun 2007 A1
20070142596 Swift et al. Jun 2007 A1
20070158022 Heep et al. Jul 2007 A1
20070184740 Keller et al. Aug 2007 A1
20070191574 Miller et al. Aug 2007 A1
20070270070 Othman Nov 2007 A1
20070287018 Tutin et al. Dec 2007 A1
20070292618 Srinivasan et al. Dec 2007 A1
20070292619 Srinivasan et al. Dec 2007 A1
20070298274 Eriksson et al. Dec 2007 A1
20080009209 Clamen et al. Jan 2008 A1
20080009616 Frank et al. Jan 2008 A1
20080051539 Kelly Feb 2008 A1
20080060551 Crews et al. Mar 2008 A1
20080081138 Moore et al. Apr 2008 A1
20080108741 Van Herwijnen et al. May 2008 A1
20080160260 Wada et al. Jul 2008 A1
20080160302 Asrar et al. Jul 2008 A1
20080194738 Crews et al. Aug 2008 A1
20090169867 Kelly Jul 2009 A1
20090170978 Kelly Jul 2009 A1
20090227732 Glockner et al. Sep 2009 A1
20090301972 Hines et al. Dec 2009 A1
20090304919 Wagner et al. Dec 2009 A1
20090306255 Patel et al. Dec 2009 A1
20090324915 Swift et al. Dec 2009 A1
20100029160 Srinivasan et al. Feb 2010 A1
20100058661 Jackson et al. Mar 2010 A1
20100080976 Jackson et al. Apr 2010 A1
20100084598 Jackson et al. Apr 2010 A1
20100086726 Jackson et al. Apr 2010 A1
20100087571 Jackson et al. Apr 2010 A1
20100098947 Inoue et al. Apr 2010 A1
20100117023 Dopico et al. May 2010 A1
20100129640 Kelly May 2010 A1
20100130649 Swift et al. May 2010 A1
20100175826 Huenig et al. Jul 2010 A1
20100210595 Wagner et al. Aug 2010 A1
20100222463 Brady et al. Sep 2010 A1
20100222566 Fosdick et al. Sep 2010 A1
20100282996 Jaffrennou et al. Nov 2010 A1
20100301256 Hampson et al. Dec 2010 A1
20100320113 Swift Dec 2010 A1
20110021672 Crews et al. Jan 2011 A1
20110039111 Shooshtari Feb 2011 A1
20110040010 Shooshtari Feb 2011 A1
20110042303 Shooshtari et al. Feb 2011 A1
20110045966 Shooshtari et al. Feb 2011 A1
20110089074 Jackson et al. Apr 2011 A1
20110135937 Swift et al. Jun 2011 A1
20110190425 Swift Aug 2011 A1
20110220835 Swift et al. Sep 2011 A1
20110256790 Toas et al. Oct 2011 A1
20110260094 Hampson et al. Oct 2011 A1
20110262648 Lee et al. Oct 2011 A1
20110263757 Rand et al. Oct 2011 A1
20110306726 Bailey et al. Dec 2011 A1
20120133073 Pacorel et al. May 2012 A1
20120156954 Eckert et al. Jun 2012 A1
20130029150 Appley Jan 2013 A1
20130032749 Jaffrennou et al. Feb 2013 A1
20130047888 Mueller et al. Feb 2013 A1
20130059075 Appley et al. Mar 2013 A1
20130082205 Mueller et al. Apr 2013 A1
20130140481 Naerum et al. Jun 2013 A1
20130174758 Mueller Jul 2013 A1
20130234362 Swift et al. Sep 2013 A1
20130236650 Swift et al. Sep 2013 A1
20130237113 Swift et al. Sep 2013 A1
20130244524 Swift et al. Sep 2013 A1
20130327250 Shooshtari Dec 2013 A1
20140091247 Jackson et al. Apr 2014 A1
20140120348 Didier et al. May 2014 A1
20140134909 Guo et al. May 2014 A1
20140357787 Jobber et al. Dec 2014 A1
Foreign Referenced Citations (137)
Number Date Country
8538765 Aug 1985 AU
9640921 Jul 1997 AU
1090026 Nov 1980 CA
2037214 Sep 1991 CA
2232334 Nov 1998 CA
2458333 Dec 1999 CA
2278946 Jan 2000 CA
2470783 Dec 2004 CA
1251738 May 2000 CN
1905054 Aug 1969 DE
4142261 Jun 1993 DE
4233622 Apr 1994 DE
4308089 Sep 1994 DE
102004033561 Sep 2005 DE
102005023431 Nov 2006 DE
0044614 Jan 1982 EP
0099801 Feb 1984 EP
0310258 Apr 1989 EP
354023 Feb 1990 EP
0375235 Jun 1990 EP
0461995 Dec 1991 EP
0524518 Jan 1993 EP
0547819 Jun 1993 EP
0583086 Feb 1994 EP
0714754 Jun 1996 EP
796681 Sep 1997 EP
0826710 Mar 1998 EP
856494 Aug 1998 EP
0873976 Oct 1998 EP
878135 Nov 1998 EP
0882756 Dec 1998 EP
0911361 Apr 1999 EP
915811 May 1999 EP
936060 Aug 1999 EP
976866 Feb 2000 EP
0990729 Apr 2000 EP
1038433 Sep 2000 EP
1193288 Apr 2002 EP
1084167 Sep 2002 EP
1268702 Jan 2003 EP
1382642 Jan 2004 EP
1486547 Dec 2004 EP
1522642 Apr 2005 EP
1521807 Mar 2006 EP
1698598 Sep 2006 EP
1767566 Apr 2007 EP
2223941 Sep 2010 EP
2253663 Nov 2010 EP
2457943 Oct 2011 EP
2549006 Jan 2013 EP
2164883 Sep 2013 EP
2576882 Feb 2015 EP
2969448 Aug 2017 EP
2614388 Oct 1988 FR
770561 Mar 1957 GB
809675 Mar 1959 GB
926749 May 1963 GB
1206193 Sep 1970 GB
1391172 Apr 1975 GB
1469331 Apr 1977 GB
1512066 May 1978 GB
1525541 Sep 1978 GB
2047258 Nov 1980 GB
2078805 Jan 1982 GB
2173523 Oct 1986 GB
2251438 Jul 1992 GB
53113784 Oct 1978 JP
57101100 Jun 1982 JP
5811193 Jan 1983 JP
61195647 Aug 1986 JP
3-173680 Jul 1991 JP
05186635 Jul 1993 JP
7-034023 Feb 1995 JP
09157627 Jun 1997 JP
10234314 Sep 1998 JP
11035491 Feb 1999 JP
11181690 Jul 1999 JP
2000327841 Nov 2000 JP
2002293576 Sep 2002 JP
2003147276 May 2003 JP
2003238921 Aug 2003 JP
2004060058 Feb 2004 JP
2005306919 Nov 2005 JP
549563 Jan 2008 NZ
1765996 Aug 1995 RU
374400 Mar 1973 SU
1990007541 Jul 1990 WO
1992012198 Jul 1992 WO
1995034517 Dec 1995 WO
1997049646 Dec 1997 WO
1999036368 Jul 1999 WO
199947765 Sep 1999 WO
199960042 Nov 1999 WO
199960043 Nov 1999 WO
200058085 Oct 2000 WO
2001014491 Mar 2001 WO
2001059026 Aug 2001 WO
200200429 Jan 2002 WO
200206178 Jan 2002 WO
2003029496 Apr 2003 WO
2003071879 Sep 2003 WO
2003106561 Dec 2003 WO
2004007615 Jan 2004 WO
2004076734 Sep 2004 WO
2005087837 Sep 2005 WO
2006044302 Apr 2006 WO
2006136614 Dec 2006 WO
2007014236 Jan 2007 WO
2007014236 Feb 2007 WO
2007024020 Mar 2007 WO
2007050964 May 2007 WO
2007112335 Oct 2007 WO
2008089847 Jul 2008 WO
2008089851 Jul 2008 WO
2008127936 Oct 2008 WO
2008141201 Nov 2008 WO
2009019235 Feb 2009 WO
2009129084 Oct 2009 WO
2010027937 Mar 2010 WO
2010106181 Sep 2010 WO
2010139899 Dec 2010 WO
2011019590 Feb 2011 WO
2011019593 Feb 2011 WO
2011019597 Feb 2011 WO
2011019598 Feb 2011 WO
2011022224 Feb 2011 WO
2011022226 Feb 2011 WO
2011022227 Feb 2011 WO
2011123593 Oct 2011 WO
WO 2011123592 Oct 2011 WO
2011138458 Nov 2011 WO
2011138459 Nov 2011 WO
2011154368 Dec 2011 WO
2013030390 Mar 2013 WO
2013150123 Oct 2013 WO
2013179323 Dec 2013 WO
2014165176 Oct 2014 WO
Non-Patent Literature Citations (233)
Entry
Written Opinion of International Searching Authority for PCT/US2015/014786, dated Aug. 13, 2015, 6 pages.
International Search Report and Written Opinion for PCT/US2008/059730, completed Sep. 22, 2008.
International Search Report and Written Opinion for PCT/US2008/069046, completed Sep. 25, 2008.
International Search Report and Written Opinion for PCT/EP2011/059317, completed Jul. 15, 2011.
International Search Report for PCT/EP2008/060185, completed Oct. 23, 2008.
International Search Report for PCT/EP2011/057363, completed Sep. 5, 2011.
Ames, J.M., “The Maillard Browning Reaction—an Update,” Chemistry & Industry, No. 17, 1988, 4 pages.
“Gamma-aminopropyltrimethoxysilane,”Hawley's Condensed Chemical Dictionary, 14th Edition, John Wiley & Sons, Inc., 2002, 1 page.
Hodge, J.E., Chemistry of Browning Reactions in Model Systems, 1953, J. Agric. Food Chem., vol. 1, No. 15, pp. 928-943.
Agyei-Aye et al., “The Role of Anion in the Reaction of Reducing Sugars with Ammonium Salts,” Carbohydrate Research 2002, 337: 2273-2277.
Laroque et al., “Kinetic study on the Maillard reaction. Consideration of sugar reactivity,” Food Chemistry 2008, 111: 1032-1042.
Bjorksten et al., “Polyester Resin—Glass Fiber Laminates,” Industrial and Engineering Chemistry (1954).
Dow Corning, “A Guide to Silane Solutions,” 2005.
Knauf Data Sheet, 2006.
Molasses Corporation, United States Sugar Corporation, http://www.suga-lik.com/molasses/composition.html (Sep. 29, 2003).
Clamen, Guy, “Acrylic Thermosets: A Safe Alternative to Formaldehyde Resins,” Nonwovens World, Apr.-May 2004, pp. 96-102.
Opposition to AU 2006272595, Amended Statement of Grounds and Particulars, issued from Australian Patent Office, Jul. 6, 2012, 22 pages.
Decision re Opposition to AU 2006272595, issued from Australian Patent Office, Aug. 14, 2015, 25 pages.
Opposition to EP 1732968, Notice of Opposition: Prior Art, Scope of the Patent, Reasons for the Opposition, issued from European Patent Office, Mar. 8, 2012, 18 pages.
Decision re Opposition to EP 1732968, issued from the European Patent Office, Nov. 14, 2014, 5 pages.
Opposition to EA 019802, submitted to Eurasian Patent Office on Dec. 26, 2014, 36 pages.
Decision re Opposition to EA 019802, issued by Eurasian Patent Office on Aug. 18, 2015, 15 pages.
Owens Corning Retiree Update: What Goes Around, Comes Around: A tale of Natural Binders, revised Mar. 20, 2013 p. 4.
A.P. Bryant, “The Terminology of Sugars,” Industrial and Engineering Chemistry, vol. 26, No. 2, p. 231, Feb. 1934.
Food Flavor Chemistry, p. 162, Mar. 21, 2009 (English Abstract).
Viswanathan, T., “Chapter 28: Thermosetting Adhesive Resins from Whey and Whey Byproducts,” in Adhesives from Renewable Resources, ACS Symposium Series, Hemingway, R.W., et al. (Eds.), American Chemical Society, Washington, DC (1989).
Viswanathan, T., and Richardson, T., “Thermosetting Adhesive Resins from Whey and Whey Byproducts,” Ind. Eng. Chem. Prod. Res. Dev. 23:644-47, American Chemical Society, United States (1984).
Residential Energy Conservation: vol. 1, Congress of the U.S., Office of Technology Assessment (Ed.), 357 pages (Jan. 1, 1979).
Office action for co-pending U.S. Appl. No. 12/524,502 (9 pages)—dated Sep. 21, 2012.
Office action for co-pending U.S. Appl. No. 12/524,502 (9 pages)—dated Apr. 4, 2013.
Office action for co-pending U.S. Appl. No. 12/524,512 (7 pages)—dated Aug. 6, 2012.
Office action for co-pending U.S. Appl. No. 12/524,512 (9 pages)—dated Apr. 1, 2013.
Office action for co-pending U.S. Appl. No. 12/524,512 (14 pages)—dated Nov. 12, 2014.
Office action for co-pending U.S. Appl. No. 12/524,512 (9 pages)—dated Jul. 10, 2015.
Office action for co-pending U.S. Appl. No. 12/524,512 (10 pages)—dated Mar. 23, 2016.
Office action for co-pending U.S. Appl. No. 12/524,512 (13 pages)—dated Oct. 5, 2016.
Office action for co-pending U.S. Appl. No. 12/524,512 (13 pages)—dated Apr. 6, 2018.
Office action for co-pending U.S. Appl. No. 12/524,512 (15 pages)—dated Jan. 17, 2019.
Office action for co-pending U.S. Appl. No. 12/524,469 (7 pages)—dated Jun. 7, 2012.
Office action for co-pending U.S. Appl. No. 12/524,469 (8 pages)—dated Jan. 29, 2013.
Office action for co-pending U.S. Appl. No. 12/524,469 (7 pages)—dated Aug. 20, 2013.
Office action for co-pending U.S. Appl. No. 12/524,469 (9 pages)—dated Jun. 9, 2014.
Office action for co-pending U.S. Appl. No. 12/524,469 (9 pages)—dated Oct. 17, 2014.
Office action for co-pending U.S. Appl. No. 12/524,469 (9 pages)—dated Jul. 23, 2015.
Office action for co-pending U.S. Appl. No. 12/524,539 (13 pages)—dated Jun. 21, 2012.
Office action for co-pending U.S. Appl. No. 12/524,539 (13 pages)—dated Jun. 6, 2013.
Office action for co-pending U.S. Appl. No. 12/524,539 (12 pages)—dated Dec. 17, 2014.
Office action for co-pending U.S. Appl. No. 12/524,539 (7 pages)—dated Jul. 15, 2015.
Office action for co-pending U.S. Appl. No. 12/524,539 (7 pages)—dated Mar. 23, 2016.
Office action for co-pending U.S. Appl. No. 12/524,539 (7 pages)—dated Dec. 29, 2016.
Office action for co-pending U.S. Appl. No. 12/524,522 (4 pages)—dated Oct. 11, 2011.
Office action for co-pending U.S. Appl. No. 12/667,718 (5 pages)—dated Sep. 3, 2013.
Office action for co-pending U.S. Appl. No. 12/667,718 (6 pages)—dated Sep. 9, 2014.
Office action for co-pending U.S. Appl. No. 12/671,922 (10 pages)—dated Oct. 7, 2011.
Office action for co-pending U.S. Appl. No. 12/671,922 (10 pages)—dated May 10, 2012.
Office action for co-pending U.S. Appl. No. 12/671,922 (9 pages)—dated Sep. 23, 2014.
Office action for co-pending U.S. Appl. No. 12/671,922 (5 pages)—dated Apr. 4, 2016.
Office action for co-pending U.S. Appl. No. 13/388,408 (5 pages)—dated Aug. 15, 2013.
Office action for co-pending U.S. Appl. No. 13/371,829 (9 pages)—dated Dec. 20, 2012.
Office action for co-pending U.S. Appl. No. 13/371,829 (6 pages)—dated Jul. 12, 2013.
Office action for co-pending U.S. Appl. No. 13/371,829 (6 pages)—dated Aug. 12, 2014.
Office action for co-pending U.S. Appl. No. 13/637,794 (8 pages)—dated Aug. 12, 2013.
Office action for co-pending U.S. Appl. No. 13/637,794 (9 pages)—dated Mar. 26, 2014.
Office action for co-pending U.S. Appl. No. 13/696,439 (11 pages)—dated Jan. 8, 2014.
Office action for co-pending U.S. Appl. No. 13/696,452 (7 pages)—dated Jan. 13, 2015.
Office action for co-pending U.S. Appl. No. 13/696,452 (9 pages)—dated Oct. 27, 2015.
Office action for co-pending U.S. Appl. No. 13/702,144 (6 pages)—dated Jan. 10, 2014.
Office action for co-pending U.S. Appl. No. 13/702,144 (7 pages)—dated Jul. 29, 2014.
Office action for co-pending U.S. Appl. No. 13/823,818 (9 pages)—dated Mar. 26, 2015.
Office action for co-pending U.S. Appl. No. 13/866,368 (16 pages)—dated Aug. 29, 2013.
Office action for co-pending U.S. Appl. No. 13/866,368 (11 pages)—dated Apr. 16, 2014.
Office action for co-pending U.S. Appl. No. 13/866,368 (8 pages)—dated Aug. 21, 2014.
Office action for co-pending U.S. Appl. No. 13/866,419 (14 pages)—dated Sep. 20, 2013.
Office action for co-pending U.S. Appl. No. 13/866,419 (10 pages)—dated Apr. 25, 2014.
Office action for co-pending U.S. Appl. No. 13/866,419 (8 pages)—dated Oct. 9, 2014.
Office action for co-pending U.S. Appl. No. 13/866,419 (8 pages)—dated Sep. 25, 2015.
Office action for co-pending U.S. Appl. No. 13/868,233 (23 pages)—dated Aug. 13, 2013.
Office action for co-pending U.S. Appl. No. 13/868,233 (12 pages)—dated Apr. 15, 2014.
Office action for co-pending U.S. Appl. No. 13/868,233 (8 pages)—dated Oct. 7, 2014.
Office action for co-pending U.S. Appl. No. 13/868,233 (8 pages)—dated Jul. 16, 2015.
Office action for co-pending U.S. Appl. No. 13/868,238 (8 pages)—dated Jul. 16, 2014.
Office action for co-pending U.S. Appl. No. 12/976,379 (7 pages)—dated Jan. 10, 2012.
Office action for co-pending U.S. Appl. No. 12/976,379 (6 pages)—dated Jul. 27, 2012.
Office action for co-pending U.S. Appl. No. 12/976,379 (9 pages)—dated Mar. 7, 2013.
Office action for co-pending U.S. Appl. No. 12/976,379 (8 pages)—dated Aug. 20, 2013.
Office action for co-pending U.S. Appl. No. 12/599,858 (8 pages)—dated May 11, 2011.
Office action for co-pending U.S. Appl. No. 13/341,542 (8 pages)—dated Dec. 26, 2012.
Office action for co-pending U.S. Appl. No. 13/341,542 (7 pages)—dated Feb. 10, 2014.
Office action for co-pending U.S. Appl. No. 14/026,394 (6 pages)—dated Aug. 14, 2014.
Office action for co-pending U.S. Appl. No. 14/272,556 (14 pages)—dated Nov. 20, 2014.
Office action for co-pending U.S. Appl. No. 14/272,556 (12 pages)—dated Sep. 17, 2015.
Office action for co-pending U.S. Appl. No. 14/342,069 (17 pages)—dated Dec. 29, 2015.
Office action for co-pending U.S. Appl. No. 14/342,069 (22 pages)—dated Sep. 2, 2016.
Office action for co-pending U.S. Appl. No. 14/342,069 (21 pages)—dated Sep. 26, 2017.
Office action for co-pending U.S. Appl. No. 14/342,069 (21 pages)—dated Jun. 6, 2018.
Office action for co-pending U.S. Appl. No. 14/649,277 (9 pages)—dated Jul. 22, 2016.
Office action for co-pending U.S. Appl. No. 14/686,915 (8 pages)—dated Nov. 18, 2016.
Office action for co-pending U.S. Appl. No. 14/810,765 (7 pages)—dated Jan. 29, 2016.
Office action for co-pending U.S. Appl. No. 14/828,916 (8 pages)—dated Nov. 25, 2016.
Office action for co-pending U.S. Appl. No. 14/867,502 (9 pages)—dated Nov. 18, 2016.
Office action for co-pending U.S. Appl. No. 15/172,432 (16 pages)—dated Apr. 17, 2017.
Office action for co-pending U.S. Appl. No. 15/702,087 (5 pages)—dated Nov. 9, 2018.
Office action for co-pending U.S. Appl. No. 15/177,442 (17 pages)—dated May 19, 2017.
Office action for co-pending U.S. Appl. No. 15/378,159 (18 pages)—dated Mar. 2, 2017.
Office action for co-pending U.S. Appl. No. 15/222,122 (8 pages)—dated Nov. 20, 2017.
Office action for co-pending U.S. Appl. No. 15/310,837 (13 pages)—dated Jun. 21, 2018.
Office action for co-pending U.S. Appl. No. 15/411,972 (9 pages)—dated Mar. 28, 2017.
Office action for co-pending U.S. Appl. No. 15/411,972 (8 pages)—dated Nov. 29, 2017.
Office action for co-pending U.S. Appl. No. 15/411,972 (9 pages)—dated Jun. 14, 2018.
Office action for co-pending U.S. Appl. No. 15/116,254 (8 pages)—dated Apr. 26, 2018.
Office action for co-pending U.S. Appl. No. 15/116,254 (10 pages)—dated Aug. 15, 2018.
Office action for co-pending U.S. Appl. No. 15/333,670 (5 pages)—dated Dec. 8, 2017.
Office Action for co-pending U.S. Appl. No. 14/116,048 (10 pages)—dated Jun. 23, 2017.
Office action for co-pending U.S. Appl. No. 15/959,131 (8 pages)—dated Nov. 8, 2019.
Office action for co-pending U.S. Appl. No. 15/822,102 (6 pages)—dated Dec. 6, 2019.
Office action for co-pending U.S. Appl. No. 15/690,623 (6 pages)—dated Jan. 9, 2020.
Other Information—Narrative of verbal disclosure of Brian Swift (1 page)—dated May 13, 2014.
Petition for Inter Partes Review of U.S. Pat. No. 8,114,210 (52 pages, filed Jun. 12, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc.).
Declaration of Dr. Frederick J. Hirsekorn Regarding U.S. Pat. No. 8,114,210 (58 pages, filed Jun. 12, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with Petition for Inter Partes Review of U.S. Pat. No. 8,114,210).
1st Petition for Inter Partes Review of U.S. Pat. No. D. 631,670 (68 pages, filed Jun. 19, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc.).
2nd Petition for Inter Partes Review of U.S. Pat. No. D. 631,670 (62 pages, filed Nov. 2, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc.).
Decision of PTAB regarding Institution of Inter Partes Review for U.S. Pat. No. D. 631,670 (33 pages)—Jan. 12, 2016.
Decision2 of PTAB regarding Institution of Inter Partes Review for U.S. Pat. No. D. 631,670 (27 pages)—May 9, 2016.
Final Written Decision of PTAB regarding Inter Partes Review of D. 631,670 based on 1st Petition (56 pages)—Jan. 11, 2017.
Final Written Decision of PTAB regarding Inter Partes Review of D. 631,670 based on 2nd Petition (55 pages)—May 8, 2017.
Court of Appeals for Federal Circuit Judgment from Appeal of PTAB Decisions in Inter Partes Reviews of U.S. Pat. No. D. 631,670 (2 pages)—Jul. 13, 2018.
1st Petition for Inter Partes Review of U.S. Pat. No. 8,940,089 (61 pages, filed Jul. 1, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc.).
Declaration of Dr. Frederick J. Hirsekorn Regarding U.S. Pat. No. 8,940,089 (70 pages, filed Jul. 1, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with 1st Petition for Inter Partes Review of U.S. Pat. No. 8,940,089).
2nd Petition for Inter Partes Review of U.S. Pat. No. 8,940,089 (56 pages, filed Jul. 10, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc.).
Declaration of Dr. Frederick J. Hirsekorn Regarding U.S. Pat. No. 8,940,089 (67 pages, filed Jul. 10, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with 2nd Petition for Inter Partes Review of U.S. Pat. No. 8,940,089).
3rd Petition for Inter Partes Review of U.S. Pat. No. 8,940,089 (62 pages, filed Jul. 17, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc.).
Declaration of Dr. Frederick J. Hirsekorn Regarding U.S. Pat. No. 8,940,089 (76 pages, filed Jul. 17, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with 3rd Petition for Inter Partes Review of U.S. Pat. No. 8,940,089).
Declaration of Dr. Elam Leed (11 pages, filed Jul. 1, Jul. 10, and Jul. 17, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with 1st, 2nd and 3rd Petition for Inter Partes Review of U.S. Pat. No. 8,940,089, respectively).
Declaration of Dr. Jonathan Vickers (10 pages, filed Jul. 1, Jul. 10, and Jul. 17, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with 1st, 2nd and 3rd Petition for Inter Partes Review of U.S. Pat. No. 8,940,089, respectively).
1st Petition for Inter Partes Review of U.S. Pat. No. 9,039,827 (60 pages, filed Jul. 29, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc.).
Declaration of Dr. Frederick J. Hirsekorn Regarding U.S. Pat. No. 9,039,827 (72 pages, filed Jul. 29, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with 1st Petition for Inter Partes Review of U.S. Pat. No. 9,039,827).
2nd Petition for Inter Partes Review of U.S. Pat. No. 9,039,827 (51 pages, filed Aug. 5, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc.).
Declaration of Dr. Frederick J. Hirsekorn Regarding U.S. Pat. No. 9,039,827 (65 pages, filed Aug. 5, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with 2nd Petition for Inter Partes Review of U.S. Pat. No. 9,039,827).
3rd Petition for Inter Partes Review of U.S. Pat. No. 9,039,827 (57 pages, filed Aug. 7, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc.).
Declaration of Dr. Frederick J. Hirsekorn Regarding U.S. Pat. No. 9,039,827 (75 pages, filed Aug. 7, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with 3rd Petition for Inter Partes Review of U.S. Pat. No. 9,039,827).
Declaration of Dr. Elam Leed (11 pages, filed Jul. 29, Aug. 5, and Aug. 7, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with 1st, 2nd and 3rd Petition for Inter Partes Review of U.S. Pat. No. 9,039,827, respectively).
Declaration of Dr. Jonathan Vickers (10 pages, filed Jul. 29, Aug. 5, and Aug. 7, 2015 by Petitioners Johns Manville Corporation and Johns Manville, Inc. in connection with 1st, 2nd and 3rd Petition for Inter Partes Review of U.S. Pat. No. 9,039,827, respectively).
Petition for Inter Partes Review of U.S. Pat. No. 9,469,747 (67 pages, filed Mar. 20, 2018 by Petitioners Johns Manville Corporation and Johns Manville, Inc.).
Petition for Inter Partes Review of U.S. Pat. No. 9,828,287 (86 pages, filed Mar. 23, 2018 by Petitioners Johns Manville Corporation and Johns Manville, Inc.).
Petition for Inter Partes Review of U.S. Pat. No. 9,464,207 (78 pages, filed Mar. 28, 2018 by Petitioners Johns Manville Corporation and Johns Manville, Inc.).
Petition for Inter Partes Review of U.S. Pat. No. 9,926,464 (74 pages, filed Mar. 30, 2018 by Petitioners Johns Manville Corporation and Johns Manville, Inc.).
Office Action Granting Ex Parte Reexamination of U.S. Pat. No. 7,888,445, dated Dec. 24, 2013, in Control No. 90/013,029, 11 pages.
Office Action Granting Ex Parte Reexamination of U.S. Pat. No. 7,772,347, dated Dec. 24, 2013, in Control No. 90/013,030, 14 pages.
Office Action Granting Ex Parte Reexamination of U.S. Pat. No. 7,854,980, dated Apr. 15, 2014, in Control No. 90/013,156, 20 pages.
Declaration of Jan Rud Andersen submitted in Ex parte Reexamination Control No. 90/013,030, as Document OTH-C, Oct. 10, 2013, 4 pages.
Final Rejection in Ex Parte Reexamination of U.S. Pat. No. 7,888,445 (20 pages)—dated Jul. 24, 2015.
Final Rejection in Ex Parte Reexamination of U.S. Pat. No. 7,772,347 (23 pages)—dated Jul. 24, 2015.
Final Rejection in Ex Parte Reexamination of U.S. Pat. No. 7,854,980 (31 pages)—dated Aug. 18, 2015.
Advisory Action in Ex Parte Reexamination of U.S. Pat. No. 7,888,445 (4 pages)—dated Oct. 6, 2015.
Advisory Action in Ex Parte Reexamination of U.S. Pat. No. 7,772,347 (4 pages)—dated Oct. 6, 2015.
Advisory Action in Ex Parte Reexamination of U.S. Pat. No. 7,854,980 (4 pages)—dated Nov. 18, 2015.
Examiner's Answer in Ex Parte Reexamination of U.S. Pat. No. 7,888,445 (8 pages)—Mar. 23, 2016.
Examiner's Answer in Ex Parte Reexamination of U.S. Pat. No. 7,772,347 (8 pages)—Mar. 23, 2016.
Examiner's Answer in Ex Parte Reexamination of U.S. Pat. No. 7,854,980 (8 pages)—Mar. 22, 2016.
Decision of PTAB in Ex Parte Reexamination of U.S. Pat. No. 7,888,445 (17 pages)—Sep. 29, 2016.
Decision of PTAB in Ex Parte Reexamination of U.S. Pat. No. 7,772,347 (18 pages)—Sep. 29, 2016.
Decision of PTAB in Ex Parte Reexamination of U.S. Pat. No. 7,854,980 (22 pages)—Sep. 30, 2016.
Court of Appeals for Federal Circuit Judgment from Consolidated Appeal of PTAB Decisions in Ex Parte Reexamination of U.S. Pat. No. 7,888,445, 7,772,347 and 7,854,980 (5 pages)—Mar. 9, 2018.
Notice of Intent to Issue Ex Parte Reexamination Certificate for U.S. Pat. No. 7,772,347 (4 pages)—dated Oct. 24, 2018.
Notice of Intent to Issue Ex Parte Reexamination Certificate for U.S. Pat. No. 7,888,445 (4 pages)—dated Dec. 7, 2018.
Notice of Intent to Issue Inter Partes Reexamination Certificate for U.S. Pat. No. 7,888,445 (14 pages)—dated Sep. 24, 2020.
Notice of Intent to Issue Inter Partes Reexamination Certificate for U.S. Pat. No. 7,772,347 (13 pages)—dated Sep. 25, 2020.
Decision of USPTO to Reopen Prosecution in Ex Parte Reexamination of U.S. Pat. No. 7,854,980 (7 pages)—Jan. 7, 2019.
Non-final Office Action from Reopened Prosecution in Ex Parte Reexamination of U.S. Pat. No. 7,854,980 (26 pages)—dated Apr. 3, 2019.
Final Office Action from Reopened Prosecution in Ex Parte Reexamination of U.S. Pat. No. 7,854,980 (11 pages)—dated Aug. 8, 2019.
Notice of Intent to Issue Ex Parte Reexamination Certificate for U.S. Pat. No. 7,854,980 (3 pages)—dated Oct. 29, 2019.
Notice of Intent to Issue Inter Partes Reexamination Certificate for U.S. Pat. No. 7,807,771 (4 pages)—dated Jan. 30, 2014.
Notice of Intent to Issue Inter Partes Reexamination Certificate for U.S. Pat. No. 7,854,980 (6 pages)—dated Aug. 31, 2017.
Decision of PTAB in Inter Partes Reexamination of U.S. Pat. No. 7,888,445 (34 pages)—May 1, 2015.
Decision of PTAB in Inter Partes Reexamination of U.S. Pat. No. 7,772,347 (36 pages)—May 1, 2015.
Decision of PTAB in Inter Partes Reexamination of U.S. Pat. No. 7,854,980 (25 pages)—Jul. 30, 2015.
Remand Order of PTAB in Inter Partes Reexamination of U.S. Pat. No. 7,888,445 (5 pages)—Dec. 9, 2015.
Remand Order of PTAB in Inter Partes Reexamination of U.S. Pat. No. 7,772,347 (5 pages)—Dec. 9, 2015.
Examiner's Determination on Patent Owner Response/Requester Comments after Board Decision in Inter Partes Reexamination of U.S. Pat. No. 7,888,445 (22 pages)—Oct. 17, 2016.
Examiner's Determination on Patent Owner Response/Requester Comments after Board Decision in Inter Partes Reexamination of U.S. Pat. No. 7,772,347 (17 pages)—Oct. 17, 2016.
Court of Appeals for Federal Circuit Opinion/Judgment from Appeal of PTAB Decision in Inter Partes Reexamination of U.S. Pat. No. 7,854,980 (13 pages)—Feb. 27, 2017.
Final Decision of PTAB in Inter Partes Reexamination of U.S. Pat. No. 7,888,445 (25 pages)—Sep. 8, 2017.
Final Decision of PTAB in Inter Partes Reexamination of U.S. Pat. No. 7,772,347 (24 pages)—Sep. 8, 2017.
Decision of PTAB re Request for Rehearing in Inter Partes Reexamination of U.S. Pat. No. 7,888,445 (7 pages)—Feb. 12, 2018.
Decision of PTAB re Request for Rehearing in Inter Partes Reexamination of U.S. Pat. No. 7,772,347 (7 pages)—Feb. 12, 2018.
Court of Appeals for Federal Circuit Decision re Consolidated Appeal of PTAB Decision in Inter Partes Reexamination of U.S. Pat. No. 7,772,347 and U.S. Pat. No. 7,888,445 (14 pages)—Oct. 15, 2019.
Remand Order of PTAB in Inter Partes Reexamination of U.S. Pat. No. 7,888,445 (3 pages)—Jul. 1, 2020.
Remand Order of PTAB in Inter Partes Reexamination of U.S. Pat. No. 7,772,347 (3 pages)—Jul. 1, 2020.
Decision of PTAB regarding Institution of Inter Partes Review for U.S. Pat. No. 8,114,210 (20 pages)—Oct. 21, 2015.
Final Written Decision of PTAB regarding Inter Partes Review of U.S. Pat. No. 8,114,210 (39 pages)—Oct. 19, 2016.
Court of Appeals for Federal Circuit Judgment from Appeal of PTAB Decision in Inter Partes Review of U.S. Pat. No. 8,114,210 (5 pages)—Jan. 16, 2018.
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 8,114,210 (11 pages)—Apr. 9, 2020.
Decision1 of PTAB declining Institution of Inter Partes Review for U.S. Pat. No. 8,940,089 (16 pages)—Dec. 17, 2015.
Decision2 of PTAB declining Institution of Inter Partes Review for U.S. Pat. No. 8,940,089 (19 pages)—Dec. 17, 2015.
Decision3 of PTAB declining Institution of Inter Partes Review for U.S. Pat. No. 8,940,089 (14 pages)—Dec. 17, 2015.
Decision1 of PTAB declining Institution of Inter Partes Review for U.S. Pat. No. 9,039,827 (16 pages)—Jan. 4, 2016.
Decision2 of PTAB declining Institution of Inter Partes Review for U.S. Pat. No. 9,039,827 (19 pages)—Jan. 4, 2016.
Decisions3 of PTAB declining Institution of Inter Partes Review for U.S. Pat. No. 9,039,827 (14 pages)—Jan. 4, 2016.
Decision of PTAB denying Institution of Inter Partes Review for U.S. Pat. No. 9,926,464 (29 pages)—Oct. 2, 2018.
Decision of PTAB denying Institution of Inter Partes Review for U.S. Pat. No. 9,464,207 (28 pages)—Oct. 2, 2018.
Decision of PTAB denying Institution of Inter Partes Review for U.S. Pat. No. 9,469,747 (29 pages)—Oct. 3, 2018.
Decision of PTAB denying Institution of Inter Partes Review for U.S. Pat. No. 9,828,287 (22 pages)—Oct. 16, 2018.
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 9,828,287 (13 pages)—Jul. 17, 2020.
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 9,464,207 (14 pages)—Jul. 31, 2020.
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 9,926,464 (18 pages)—Aug. 5, 2020.
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 8,940,089 (17 pages)—Oct. 16, 2020.
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 9,039,827 (16 pages)—Oct. 16, 2020.
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 9,469,747 (16 pages)—Nov. 9, 2020.
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 9,464,207 (19 pages)—Aug. 27, 2021.
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 9,926,464 (16 pages)—Sep. 7, 2021.
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 9,469,747 (10 pages)—Sep. 16, 2021.
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 8,114,210 (13 pages)—Dec. 1, 2021.
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 8,940,089 (13 pages)—Jan. 28, 2022.
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 9,828,287 (11 pages)—Feb. 1, 2022.
Decision of USPTO Granting Ex Parte Re-exam of U.S. Pat. No. 9,039,827 (13 pages)—Feb. 1, 2022.
Notice of Intent to Issue Ex Parte Reexamination Certificate for U.S. Pat. No. 8,114,210 (4 pages)—dated May 27, 2021.
Notice of Intent to Issue Ex Parte Reexamination Certificate for U.S. Pat. No. 9,464,207 (4 pages)—dated Apr. 19, 2021.
Notice of Intent to Issue Ex Parte Reexamination Certificate for U.S. Pat. No. 9,828,287 (5 pages)—dated May 5, 2021.
Notice of Intent to Issue Ex Parte Reexamination Certificate for U.S. Pat. No. 9,926,464 (5 pages)—dated May 5, 2021.
Notice of Intent to Issue Ex Parte Reexamination Certificate for U.S. Pat. No. 9,469,747 (8 pages)—dated May 21, 2021.
Notice of Intent to Issue Ex Parte Reexamination Certificate for U.S. Pat. No. 9,039,827 (3 pages)—dated Jul. 2, 2021.
Notice of Intent to Issue Ex Parte Reexamination Certificate for U.S. Pat. No. 8,940,089 (4 pages)—dated Jul. 13, 2021.
Petition for Post Grant Review of U.S. Pat. No. 10,968,629 (50 pages, filed Jan. 6, 2022 by Petitioner Rockwool International A/S).
Statement of Revocation Grounds re GB2496951-Claimant Rockwool International (May 21, 2018, 22 pages).
Statement of Revocation Grounds re GB2451719-Claimant Rockwool International (May 18, 2018, 22 pages).
Expert Report re Revocation of GB2451719 and GB2496951-Claimant Rockwool International (Nov. 12, 2018, 11 pages).
United Kingdom Intellectual Property Office, Decision in Rockwool International v. Knauf Insulation Limited, Application under Section 72 for revocation of patents GB2451719 and GB2496951 (May 28, 2019—18 pages).
Decision of EPO Board of Appeal re Added Matter vis-á-vis EP06788492.4 (Jul. 17, 2019—14 pages).
Re U.S. Pat. No. 2,965,504—Part 1 (10 pages).
Re U.S. Pat. No. 2,965,504—Part 2 (14 pages).
Re U.S. Pat. No. 2,965,504—Part 3 (14 pages).
Gogek Attorney Comments re U.S. Pat. No. 2,965,504—Apr. 6, 1960 (3 pages).
Gogek Affidavit Under Rule 132 re U.S. Pat. No. 2,965,504—Feb. 26, 1960 (3 pages).
Related Publications (1)
Number Date Country
20160347652 A1 Dec 2016 US
Provisional Applications (1)
Number Date Country
61937110 Feb 2014 US